Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTCs Could Benefit From Flexible Spending Account Surpluses – Suydam

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association is focusing a campaign to inform OTC drug manufacturers that over-the-counter drug expenses can now be redeemed under flexible spending accounts

You may also be interested in...



Push For FSA Eligibility For “Preventive” OTCs, Supplements Predicted

A wave of lobbying to expand the types of nonprescription health remedies that can be reimbursed through flexible spending accounts is on the way, American Pharmacy Association VP-Policy & Communications Susan Winckler predicted at an IIR-sponsored Rx-to-OTC switch conference in Philadelphia Nov. 20

Push For FSA Eligibility For “Preventive” OTCs, Supplements Predicted

A wave of lobbying to expand the types of nonprescription health remedies that can be reimbursed through flexible spending accounts is on the way, American Pharmacy Association VP-Policy & Communications Susan Winckler predicted at an IIR-sponsored Rx-to-OTC switch conference in Philadelphia Nov. 20

Push For FSA Eligibility For “Preventive” OTCs, Supplements Predicted

A wave of lobbying to expand the types of nonprescription health remedies that can be reimbursed through flexible spending accounts is on the way, American Pharmacy Association VP-Policy & Communications Susan Winckler predicted at an IIR-sponsored Rx-to-OTC switch conference in Philadelphia Nov. 20

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel